TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01940016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: communication intervention
Description: Participants participate in a 12-week physical activity intervention (walking program)and receive health mail messages via IVR system and had the option of communicating with a health coach.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention
Description: Participants participate in a 12-week physical activity intervention administered using an IVR system.
Study: NCT03546608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: Participants received a single oral dose of tepotinib in Part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: Participants received a single oral dose of tepotinib in Part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: Participants received a single oral dose of tepotinib in Part 1.
Study: NCT04765163

Intervention type: DEVICE
Intervention: Intelligent Operating Handle
Description: Intelligent Operating Handle
Study: NCT01940016

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise intervention
Description: Participants participate in a 12-week physical activity intervention administered using an IVR system.
Study: NCT04520022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Umbilical Cord Blood-derived Mesenchymal Stem Cells
Description: 3.0 x 106 cells/kg, IV, Total of 3 doses every 2weeks
Study: NCT01639638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PROAPOPTOTIC PEPTIDE CIGB 300
Description: CIGB 300,in INTRALESIONAL on day 3 of each 48 HOURS.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PROAPOPTOTIC PEPTIDE CIGB 300
Description: CIGB 300,in INTRALESIONAL on day 3 of each 48 HOURS.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PROAPOPTOTIC PEPTIDE CIGB 300
Description: CIGB 300,in INTRALESIONAL on day 3 of each 48 HOURS.
Study: NCT02925000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC178
Description: TLC178
Study: NCT02517307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralipid/Heparin
Description: Co-infusion of intralipid and heparin solutions during a hyperinsulinemic euglycemic clamp

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralipid/Heparin
Description: Co-infusion of intralipid and heparin solutions during a hyperinsulinemic euglycemic clamp

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycerol/Saline
Description: Co-infusion of a glycerol/saline solutions during a hyperinsulinemic euglycemic clamp

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycerol/Saline
Description: Co-infusion of a glycerol/saline solutions during a hyperinsulinemic euglycemic clamp

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic euglycemic clamp
Description: Infusion of insulin at at 40 mU/m2/min for 5 hours. Blood glucose will be monitored every 5 min during the insulin infusion and euglycemia will be maintained throughout the clamp by infusing 20% dextrose at a variable rate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic euglycemic clamp
Description: Infusion of insulin at at 40 mU/m2/min for 5 hours. Blood glucose will be monitored every 5 min during the insulin infusion and euglycemia will be maintained throughout the clamp by infusing 20% dextrose at a variable rate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic euglycemic clamp
Description: Infusion of insulin at at 40 mU/m2/min for 5 hours. Blood glucose will be monitored every 5 min during the insulin infusion and euglycemia will be maintained throughout the clamp by infusing 20% dextrose at a variable rate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic euglycemic clamp
Description: Infusion of insulin at at 40 mU/m2/min for 5 hours. Blood glucose will be monitored every 5 min during the insulin infusion and euglycemia will be maintained throughout the clamp by infusing 20% dextrose at a variable rate.
Study: NCT03360552

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidimensional fragility index questionnaire RAI-Home Care
Description: Questionnaire for assessing deficits in Alzheimer's disease

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Usual clinical evaluation
Study: NCT02375581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: 125mg, Po, TID during RT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic radiotherapy
Description: involved-Field irradiaton without elective nodal irradiation
Study: NCT04100798

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Entire Papilla Preservation technique
Description: A minimally invasive technique that allow access to the intrabony defect without affecting the interdental papilla related to it
Study: NCT02375581

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic radiotherapy
Description: involved-Field irradiaton without elective nodal irradiation
Study: NCT04100798

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified Minimally invasive Surgical Technique
Description: a minimally invasive technique that allow access to the intrabony defect area from the buccal aspect through a horizontal incision below the papilla without elevating it.
Study: NCT03794141

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: information on the risk gene status
Description: information on risk gene status (APOE4 allele or not) was given before intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: information on the risk gene status
Description: information on risk gene status (APOE4 allele or not) was given before intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: life style advise
Description: all test persons were given information on healthy diet and life style

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: life style advise
Description: all test persons were given information on healthy diet and life style

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: life style advise
Description: all test persons were given information on healthy diet and life style
Study: NCT02270892

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera treatment
Description: Focused ultrasound energy delivered below the surface of the skin

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera treatment
Description: Focused ultrasound energy delivered below the surface of the skin
Study: NCT04062851

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Gastric residual volume monitoring
Description: Gastric residual volumes will not be monitored
Study: NCT00660504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amrubicin Hydrochloride
Description: Amrubicin Hydrochloride combined with cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide-Cisplatin combined chemotherapy
Description: combined chemotherapy
Study: NCT04725370

Intervention type: OTHER
Intervention: NA - survey instrument
Description: Survey instrument was administered verbally to parents of the Guatemalan cohort.
Study: NCT00465855

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen (HBO2) - 3 sessions
Description: Before patients are offered an opportunity to participate in this study, they will receive a single hyperbaric oxygen session. During the first session, hyperbaric oxygen will be administered at 3.0 atmospheres absolute (atm abs) for 25 minutes breathing oxygen, 5 minutes air breathing, 25 minutes oxygen breathing, 5 minutes air breathing, pressure reduced to 2.0 atm abs for 30 minutes breathing oxygen, 5 minutes air breathing, and 30 minutes oxygen breathing.~For the second and third hyperbaric oxygen sessions, the subject will breathe 100% oxygen delivered at 2 atm abs for 90 minutes with two 5-minute air breathing periods.

Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Hyperbaric Oxygen (HBO2) - 1 session
Description: During the first session, hyperbaric oxygen will be administered at 3.0 atmospheres absolute (atm abs) for 25 minutes breathing oxygen, 5 minutes air breathing, 25 minutes oxygen breathing, 5 minutes air breathing, pressure reduced to 2.0 atm abs for 30 minutes breathing oxygen, 5 minutes air breathing, and 30 minutes oxygen breathing.~The second and third chamber sessions are sham sessions: room air delivered at 1.0 atmospheres absolute for 90 minutes with two sham 5-minute air breathing periods.
Study: NCT01337011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: autologous CD133pos stem cell application
Description: The study aims to show efficacy of both intra-myocardial autologous CD133pos bone marrow cell application as well as intra-coronary CD133pos cell application in patients with symptomatic ischemic heart disease. In addition, efficacy between the two delivery routes will be compared.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: autologous CD133pos stem cell application
Description: The study aims to show efficacy of both intra-myocardial autologous CD133pos bone marrow cell application as well as intra-coronary CD133pos cell application in patients with symptomatic ischemic heart disease. In addition, efficacy between the two delivery routes will be compared.
Study: NCT02820376

Intervention type: OTHER
Group type: OTHER
Intervention: Differential renal function assessment by 4D CT
Description: Low dose 4D (perfusion) renal acquisition after injection of iodinated contrast medium (ICM) (13 passes every 3 seconds, 3 passes every 10 seconds); estimated additional DLP 400 mGy.cm No additional contrast medium
Study: NCT01428635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag Olamine
Description: Given PO
Study: NCT00928668

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo device for comparison
Study: NCT02162420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Alemtuzumab 0.2 mg/kg IV over 2 hours on days -10 to -6 from transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 40 mg/m2 IV over 1 hour on days -6 to -2 from transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 40 mg/m2 IV over 1 hour on days -6 to -2 from transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 50 mg/kg IV over 2 hours on day -7 from transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 50 mg/kg IV over 2 hours on day -7 from transplant.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: TBI 200 cGy as a single fraction on day -1 from transplant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Stem cell transplant on day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Stem cell transplant on day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin
Description: ATG (Thymoglobulin - Rabbit ) 3 mg/kg IV on days -5 to -3 from stem cell transplant.
Study: NCT00420316

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix (primary vaccination study)
Description: GlaxoSmithKline Biologicals' oral live attenuated human rotavirus vaccine.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (primary vaccination study)
Description: Two liquid oral doses of placebo
Study: NCT04296513

Intervention type: DIAGNOSTIC_TEST
Intervention: High-Definition white light endoscopy.
Description: evaluation of the gastric mucosa with high-definition white light endoscopy (EG-29i10 gastroscope and EPKi7010 video processor). The endoscopy images will be seen on a 27inch, flat panel, high definition LCD monitor (Radiance™ ultraSC-WU27-G1520 model) by

Intervention type: DIAGNOSTIC_TEST
Intervention: High-definition magnification with digital chromoendoscopy.
Description: Subject will be evaluated by upper endoscopy with the OE System (EPK-i7010 HD Video Processor and MagniView™ EG-2990Zi Video Gastroscope) with intravenous sedation in a standardized manner. This technique involves the use of a distal black rubber hood (OE-A58; Pentax) at the tip of the endoscope, to fix the distance between the tip of the endoscope and the gastric mucosa at 2 mm. The OE System will be used in mode 1 and mode 2 without optical magnification, to obtain an overview of the gastric body and identify any gross changes in the mucosa, then optical magnification will be implemented.
Study: NCT01491698

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-en-Y pouch reconstruction (RYP)
Description: Patients will be consented to the study and complete pre-surgical questionnaires. Final randomization will occur once the surgeon in the operating room has confirmed eligibility intraoperatively. The envelope will be opened, and the patient randomized to either receive RYP or RYC. There are no restrictions on how surgeons may create the RYC or RYP reconstruction, except that the pouch must be a minimum of 15 cm in length (from esophago-jejunal anastomosis to end of jejuno-jejunal anastomosis).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional Roux-en-Y reconstruction (RYC)
Description: Patients will be consented to the study and complete pre-surgical questionnaires. Final randomization will occur once the surgeon in the operating room has confirmed eligibility intraoperatively. The envelope will be opened, and the patient randomized to either receive RYP or RYC. There are no restrictions on how surgeons may create the RYC or RYP reconstruction, except that the pouch must be a minimum of 15 cm in length (from esophago-jejunal anastomosis to end of jejuno-jejunal anastomosis).
Study: NCT01975311

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbopelvic Manipulation
Description: High-velocity low-amplitude non-specific lumbopelvic thrust manipulation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Passive lumbar spine flexion and extension
Description: Passive lumbar spine flexion and extension without reaching the physiological end feel for 1 min from a side lying position.
Study: NCT00928668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol (BI1744CL)
Description: Olodaterol comparison of low, medium low, medium high and high doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol (BI1744CL)
Description: Olodaterol comparison of low, medium low, medium high and high doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol (BI1744CL)
Description: Olodaterol comparison of low, medium low, medium high and high doses
Study: NCT01035255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696 200 mg BID
Description: LCZ696 200 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril 10 mg BID
Description: Enalapril 10 mg BID
Study: NCT01308320

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl citrate
Description: According to the enrolled group, certain dose of fentanyl is intravenously administered by bolus just after sevoflurane discontinuation.
Study: NCT00570570

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physiotherapy
Description: trice a week during 6 weeks
Study: NCT01308320

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl citrate
Description: According to the enrolled group, certain dose of fentanyl is intravenously administered by bolus just after sevoflurane discontinuation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl citrate
Description: According to the enrolled group, certain dose of fentanyl is intravenously administered by bolus just after sevoflurane discontinuation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: According to the enrolled group, certain dose of saline is intravenously administered by bolus just after sevoflurane discontinuation.
Study: NCT02946879

Intervention type: BIOLOGICAL
Intervention: AAV OPTIRPE65
Description: comparison of different doses of AAV RPE65

Intervention type: BIOLOGICAL
Intervention: AAV OPTIRPE65
Description: comparison of different doses of AAV RPE65

Intervention type: BIOLOGICAL
Intervention: AAV OPTIRPE65
Description: comparison of different doses of AAV RPE65
Study: NCT00782665

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biopsy
Description: 1 centimeter x 1/2 centimeter piece cut from uterus

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: 1 centimeter x 1/2 centimeter piece cut from uterus
Study: NCT03262597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enterade
Description: Subjects will consume enterade, which is an amino acid-based oral rehydration solution.
Study: NCT02749760

Intervention type: OTHER
Group type: OTHER
Intervention: Strengthening program
Description: Strengthening programs may be established to target the stabilizers of the elbows

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise program
Description: Exercise program may be established to target the stabilizers of the elbows.
Study: NCT03262597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pedialyte
Description: Subjects will consume Pedialyte
Study: NCT03628794

Intervention type: DEVICE
Group type: OTHER
Intervention: D-SCAN
Description: Subjects will receive a digital patient navigator service in the form of a mobile application (app), which has been designed at Duke, with feedback from Duke Cancer Institute (DCI) patients, caregivers and clinicians. Its purpose is to facilitate awareness of available Cancer Patient Support Program (CPSP) services at Duke, and to also help patients recognize their unmet symptom management needs. Subjects receiving the D-SCAN mobile app will also complete a survey every week within the app. The first 15 patients and 5 caregivers randomized into the intervention arm (those receiving the app) will also be asked to participate in a qualitative interview assessment at week 12, +/- 3 weeks

Intervention type: DEVICE
Group type: OTHER
Intervention: D-SCAN
Description: Subjects will receive a digital patient navigator service in the form of a mobile application (app), which has been designed at Duke, with feedback from Duke Cancer Institute (DCI) patients, caregivers and clinicians. Its purpose is to facilitate awareness of available Cancer Patient Support Program (CPSP) services at Duke, and to also help patients recognize their unmet symptom management needs. Subjects receiving the D-SCAN mobile app will also complete a survey every week within the app. The first 15 patients and 5 caregivers randomized into the intervention arm (those receiving the app) will also be asked to participate in a qualitative interview assessment at week 12, +/- 3 weeks
Study: NCT03262597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gatorade
Description: Subjects will consume Gatorade

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: Subjects will consume water as the control beverage
Study: NCT04289415

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support
Description: Employment specialist will work together with the participants in accordance to the method IPS in order to help the participant obtain competitive employment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Placement and Support
Description: Employment specialist will work together with the participants in accordance to the method IPS in order to help the participant obtain competitive employment
Study: NCT03682510

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stepwise devascularization
Description: stepwise devascularization begins with suture the placenta bed through uterine artery ligation, internal iliac artery ligation etc

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: B-Lynch Transverse Compression Suture group
Description: After acceptable control of bleeding from the placental bed, uses the suture material 1 VICRYL with a 70mm ½ circle needle mounted on a 90 cms VICRYL suture. We use the needle blunt ended to puncture the uterus 3 cms above the upper margin of the incision posteriorly and behind the vascular bundle.~The needle is retrieved through the cavity of the uterus and pulled inferiorly with the suture material lying on the posterior wall of the uterine cavity. The needle then perforates the posterior wall of the uterus 3 cms below the inferior margin of the Caesarean incision and exists behind the vascular bundle of the same side of the uterus retrieved and runs on the surface of the lower segment below the incision margin parallel to it and taking a 1 cm bite of tissue for stabilization running to the other side. After encircling the para-uterine vasculature, the needle then perforates the posterior side of the uterus behind the vascular bundle entering the uterine cavity.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: N&H sandwich technique
Description: In the N\&H group, double uterine compression suture at the lower uterine segment with inflated Foley's catheter balloon tamponade.
Study: NCT02290054

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Implementation of adhesive pads on the ears is performed while the patient is sleeping but before thoracic incision.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treated
Description: Auriculotherapy uses semi-permanent needles and implementation of adhesive pads to mask the needles.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Intra-venous anesthesia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-venous anesthesia
Study: NCT03826355

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CO2 (carbon dioxide) laser vaporisation
Description: CO2 (carbon dioxide) laser is used to vaporise the inner wall of the endometrioma

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stripping technique
Description: Identification of a cleavage plane and perform the cystectomy removing all the wall of the endometrioma from the healthy ovarian tissue
Study: NCT02531568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3995